HUBILO
2.2.2021 16:20:05 CET | Business Wire | Press release
Event technology company Hubilo has updated its virtual event platform to include support for all the European languages, to meet the demands of a growing global market for virtual events which is expected to be worth over $400bn by 2027.
Hubilo’s platform offers customers a DIY (Do It Yourself) feature that allows them to create events based on individual specifications using a few basic steps, including customizing events in their chosen language to make the entire process simple to understand and operate. The new multilingual feature enables Hubilo to support customers across Europe better, creating a truly universal hub.
Additional Features include a networking lounge where attendees can connect and video chat with the ones with similar interests, virtual booths that provide businesses and promoters with a separate online space to market their products, speaker lounges where attendees can see a list of all event speakers and their sessions and register and add sessions to their event itinerary, live and on-demand sessions, surveys and polls , gamification experiences , automated registrations and ticket processes, and 24/7 customer care services.
For the organizers, there is a provision of features like analytics and insights to help them with quality lead assessments for conversions, a system of records that acts as a reference point to ensure that the organizers have a complete understanding of the attendee engagement rate and interactions along with other required insights across various touchpoints at the event, a broadcast studio which eliminates the need of an additional video conference software, at the same time shares all the tools that are provided by the external software and branded themes , here you can customize your event as per your brand guideline to deliver the precise brand messaging.
Vaibhav Jain, Founder and CEO, Hubilo said: “We launched our virtual platform to deliver a richer online experience for organizers and attendees, mirroring numerous positive features of in-person events along with the addition of a few advanced ones. We are glad that we are able to offer a more inclusive range of languages to our existing, and new as well as prospective clients across Europe. In fact, in order to comply with the European rules and regulations, Hubilo will also now host information on European clients and attendees on dedicated EU servers, within the European jurisdiction.”
Hubilo, which lists Roche, GITEX and Informa Group among its customers, managed to pivot to deliver online virtual events in February 2020, backed by a $4.5m investment led by Lightspeed Venture Partners. Hubilo covers the entire spectrum of meetings, incentives, conferences, and exhibitions (MICE) for external and internal events such as trade fairs, job fairs, award shows, annual sales meet, employee engagement initiatives, town halls, office parties and more.
About Hubilo :
Event technology Company Hubilo has created a comprehensive virtual platform that meets all the event-based requirements through the integration of numerous technology tools. They have redefined the entire marketing landscape around virtual events to unlock massive value for key stakeholders, such as CMOs, event organizers, and sponsors. Hubilo covers the entire spectrum of meetings, incentives, conferences and exhibitions (MICE) which include FMCG, BFSI, Education, Healthcare and Pharmaceutical, Information Technology and Manufacturing, as well as several other industries. Founded in 2015 and pivoted in February 2020 by Vaibhav Jain and Mayank Agarwal, in just 5 years, Hubilo's clientele is inclusive of names like United Nations, Roche, Informa Markets, Tech in Asia, Fortune, AWS, Siemens, GITEX, to name a few.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210202005812/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom